Report cover image

Recombinant Erythropoietin Market

Publisher Coherent Market Insights
Published Jul 04, 2023
Length 170 Pages
SKU # CMI18107603

Description

Recombinant Erythropoietin Market, By Type of Recombinant Erythropoietin (Epoetin Alfa, Darbepoetin Alfa), By Route of Administration (Subcutaneous, Intravenous), By Indication (Anemia Associated with Chronic Kidney Disease (CKD), Cancer-Related Anemia, HIV-Associated Anemia, Others), By End-user (Hospitals and Clinics, Dialysis Centers, Oncology Centers, Others), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030


Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This breakthrough has provided has provided a highly effective and targeted approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administrating rEPO, healthcare professionals can stimulate RBC production, improving oxygen carrying capacity and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusion and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

Rising prevalence of chronic kidney disease (ckd), increased incidence of cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. Moreover, growing aging population, advancements in biotechnology is also expected to boost the growth of the global recombinant erythropoietin market over the forecast period. Emerging markets, untapped therapeutic areas, biosimilars, and collaborations and partnerships are expected to create growth opportunities for the global recombinant erythropoietin market during the forecast period.

However, stringent regulatory requirements, safety concerns and side effects, reimbursement challenges are expected to hamper growth of the recombinant erythropoietin market over the forecast period.

Key features of the study:
  • This report provides in-depth analysis of the global Recombinant Erythropoietin Market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Recombinant Erythropoietin Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Roche Holding AG, Novartis AG, Biocon Limited, Teva Pharmaceutical Industries Ltd., LG Chem Ltd., Sandoz International GmbH (a subsidiary of Novartis AG), Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., CJ CheilJedang Corporation, BioSidus SA
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Recombinant Erythropoietin Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Recombinant Erythropoietin Market
Detailed Segmentation:
  • Global Recombinant Erythropoietin Market, By Type of Recombinant Erythropoietin:
  • Epoetin Alfa
  • Darbepoetin Alfa
  • Global Recombinant Erythropoietin Market, By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Global Recombinant Erythropoietin Market, By Indication:
  • Anemia Associated with Chronic Kidney Disease (CKD)
  • Cancer-Related Anemia
  • HIV-Associated Anemia
  • Others
  • Global Recombinant Erythropoietin Market, By End User:
  • Hospitals and Clinics
  • Dialysis Centers
  • Oncology Centers
  • Others
  • Global Recombinant Erythropoietin Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • Company Profiles:
  • Amgen Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd.
  • LG Chem Ltd.
  • Sandoz International GmbH (a subsidiary of Novartis AG)
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion Inc.
  • 3SBio Inc.
  • CJ CheilJedang Corporation
  • BioSidus SA

Table of Contents

170 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Type of Recombinant Erythropoietin
Market Snapshot, By Route of Administration
Market Snapshot, By Indication
Market Snapshot, By End User
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Rising prevalence of chronic kidney disease (ckd)
Increased incidence of cancer
Growing aging population
Restraints
Growing Focus on Biosimilars
Shift towards Long-Acting Formulations
Focus on Patient-Centric Delivery Systems
Opportunities
Emerging Markets
Untapped Therapeutic Areas
Biosimilars
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Recombinant Erythropoietin Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Recombinant Erythropoietin Market , By Type of Recombinant Erythropoietin, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Epoetin Alfa
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Darbepoetin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
6. Global Recombinant Erythropoietin Market , By Route of Administration, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
7. Global Recombinant Erythropoietin Market, By Indication, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Anemia Associated with Chronic Kidney Disease (CKD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Cancer-Related Anemia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
HIV-Associated Anemia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
8. Global Recombinant Erythropoietin Market , By End User, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Hospitals and Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Dialysis Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Oncology Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
9. Global Recombinant Erythropoietin Market , By Region, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, By Country, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Country 2018 –2030
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
Middle East & Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type of Recombinant Erythropoietin , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication , 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User , 2023-2030,(US$ Bn)
10. Competitive Landscape
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson (Janssen Pharmaceuticals)
Pfizer Inc.
Roche Holding AG
Novartis AG
Biocon Limited
Teva Pharmaceutical Industries Ltd.
LG Chem Ltd.
Sandoz International GmbH (a subsidiary of Novartis AG)
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Celltrion Inc.
3SBio Inc.
CJ CheilJedang Corporation
BioSidus SA
Analyst Views
11. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on "Global Recombinant Erythropoietin Market” - Global forecast to 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us